vinflunine
Sign in to saveVinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.
Research
340 papers- Vinflunine.Drugs · 2010
- Vinflunine.Prescrire international · 2011
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.Annals of oncology : official journal of the European Society for Medical Oncology · 2019
- Vinflunine for the treatment of non-small cell lung cancer.Expert opinion on investigational drugs · 2016
- Vinflunine.IDrugs : the investigational drugs journal · 2004
via PubMed
~2 min read
Encyclopedic overview
4 sectionsContents
- Approvals and indications
- Clinical trials
- References
- External links
Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.
On November 23, 2007, Pierre Fabre Medicament and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008."
Excerpted from Wikipedia’s “vinflunine” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0